Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | +3.47% | +7.19% | -45.51% |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Apr. 11 | Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.51% | 39.33M | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating